NCT06165900View on ClinicalTrials.gov

Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC

PHASE2RecruitingINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

September 26, 2023

Primary Completion Date

December 15, 2025

Study Completion Date

December 15, 2028

Conditions
Stereotactic RadiotherapyImmunotherapyBreast Cancer
Interventions
DRUG

adebrelimab plus stereotactic radiotherapy followed by adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)

Adebrelimab plus radiotherapy phase: radiotherapy was started on the day of the second cycle of adebrelimab administration every other day for 3 fractions; Adebrelimab plus chemotherapy phase: starting within 3-5 weeks after completion of radiotherapy, every 3 weeks for 6 cycles.

DRUG

adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)

adebrelimab plus chemotherapy (nab-paclitaxel + carboplatin)

Trial Locations (1)

110022

RECRUITING

Shengjing Hospital of China Medical University, Shenyang

All Listed Sponsors
lead

Shengjing Hospital

OTHER